These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 14618190)

  • 21. Introduction: fusidic acid enters the United States.
    Moellering RC; Corey GR; Grayson ML
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S467-8. PubMed ID: 21546622
    [No Abstract]   [Full Text] [Related]  

  • 22. Staphylococcus aureus resistant to fusidic acid among Swedish children: a follow-up study.
    Osterlund A; Kahlmeter G; Haeggman S; Olsson-Liljequist B;
    Scand J Infect Dis; 2006; 38(5):334-4. PubMed ID: 16724423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fusidic acid resistance in Staphylococcus aureus.
    Dobie D; Gray J
    Arch Dis Child; 2004 Jan; 89(1):74-7. PubMed ID: 14709515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A fusidic acid-resistant clone of Staphylococcus aureus associated with impetigo bullosa is spreading in Norway.
    Tveten Y; Jenkins A; Kristiansen BE
    J Antimicrob Chemother; 2002 Dec; 50(6):873-6. PubMed ID: 12461006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The decline of the impetigo epidemic caused by the epidemic European fusidic acid-resistant impetigo clone: an 11.5-year population-based incidence study from a community in Western Norway.
    Rørtveit S; Skutlaberg DH; Langeland N; Rortveit G
    Scand J Infect Dis; 2014 Dec; 46(12):832-7. PubMed ID: 25229166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of fusidic acid in therapy of experimental Staphylococcus aureus meningitis.
    Østergaard C; Yieng-Kow RV; Knudsen JD; Frimodt-Møller N; Espersen F
    J Antimicrob Chemother; 2003 May; 51(5):1301-5. PubMed ID: 12697637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Monitoring of the resistance to antibiotics of Staphylococcus aureus strains isolated from out-patients].
    Văduva DB; Licker M; Dumitraşcu V; Văduva MB; Velimirovici D; Linţa M; Horhat F; Orb CE; Crăciunescu M; Branea D; Hogea E; Horhat D; Moldovan R
    Bacteriol Virusol Parazitol Epidemiol; 2005; 50(1-2):41-8. PubMed ID: 17300030
    [No Abstract]   [Full Text] [Related]  

  • 28. Where to from here? The treatment of impetigo in children as resistance to fusidic acid emerges.
    Vogel A; Lennon D; Best E; Leversha A
    N Z Med J; 2016 Oct; 129(1443):77-83. PubMed ID: 27736855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Staphylococcal and streptococcal pyodermas.
    Feingold DS
    Semin Dermatol; 1993 Dec; 12(4):331-5. PubMed ID: 8312149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emergence of linezolid resistance in a methicillin resistant Staphylococcus aureus strain.
    Hentschke M; Saager B; Horstkotte MA; Scherpe S; Wolters M; Kabisch H; Grosse R; Heisig P; Aepfelbacher M; Rohde H
    Infection; 2008 Feb; 36(1):85-7. PubMed ID: 18165857
    [No Abstract]   [Full Text] [Related]  

  • 31. Sensitivity of antibacterials of Staphylococcus aureus isolated from impetigo patients.
    Nishijima S; Nakagawa M
    J Int Med Res; 1997; 25(4):210-3. PubMed ID: 9283995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Impetigo contagiosa (staphylococcal, streptococcal].
    Takahashi H
    Ryoikibetsu Shokogun Shirizu; 1999; (23 Pt 1):560-3. PubMed ID: 10088470
    [No Abstract]   [Full Text] [Related]  

  • 33. [Impetigo in French Guyana. A clinical, bacteriological, toxicological and sensitivity to antibiotics study].
    Couppié P; Sainte-Marie D; Prévost G; Gravet A; Clyti E; Moreau B; Monteil H; Pradinaud R
    Ann Dermatol Venereol; 1998 Oct; 125(10):688-93. PubMed ID: 9835957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial.
    Koning S; van Suijlekom-Smit LW; Nouwen JL; Verduin CM; Bernsen RM; Oranje AP; Thomas S; van der Wouden JC
    BMJ; 2002 Jan; 324(7331):203-6. PubMed ID: 11809642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impetigo: etiology and therapy.
    Hirschmann JV
    Curr Clin Top Infect Dis; 2002; 22():42-51. PubMed ID: 12520646
    [No Abstract]   [Full Text] [Related]  

  • 36. [Antibiotic susceptibility of Staphylococcus aureus strains responsible for community-acquired skin infections].
    Bernard P; Jarlier V; Santerre-Henriksen A
    Ann Dermatol Venereol; 2008 Jan; 135(1):13-9. PubMed ID: 18342068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bacteriological studies in the therapy of treatment-resistant staphylococcal infections with fusidic acid].
    Roser H
    Med Welt; 1967 May; 21():1325-9. PubMed ID: 5612546
    [No Abstract]   [Full Text] [Related]  

  • 38. [Managing children skin and soft tissue infections].
    Moulin F; Quinet B; Raymond J; Gillet Y; Cohen R
    Arch Pediatr; 2008 Oct; 15 Suppl 2():S62-7. PubMed ID: 19000857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fusidic acid: new opportunities with an old antibiotic.
    Anderson JD
    Can Med Assoc J; 1980 Apr; 122(7):765-9. PubMed ID: 6988070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Epidemiology of the resistance of Staphylococcus aureus to antimicrobials].
    Cercenado Mansilla E
    Rev Esp Quimioter; 2006 Mar; 19(1):83-4. PubMed ID: 16688297
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.